A randomized trial of bevacizumab for newly diagnosed glioblastoma.

  title={A randomized trial of bevacizumab for newly diagnosed glioblastoma.},
  author={Mark R. Gilbert and James J. Dignam and Terri S. Armstrong and Jeffrey Scott Wefel and Deborah T. Blumenthal and Michael A. Vogelbaum and Howard Colman and Arnab Chakravarti and Stephanie L. Pugh and M. C. Won and Robert Jeraj and P D Brown and Kurt A. Jaeckle and David Schiff and Volker W. Stieber and David G. Brachman and Maria Werner-Wasik and Ivo W. Tremont-Lukats and Erik P. Sulman and Kenneth D. Aldape and Walter J. Curran and Minesh P. Mehta},
  journal={The New England journal of medicine},
  volume={370 8},
BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known. METHODS In this randomized, double-blind, placebo… CONTINUE READING
Highly Influential
This paper has highly influenced 36 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 29 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 510 extracted citations


Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…